Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Article in English | MEDLINE | ID: mdl-38826137

ABSTRACT

Clinical experience with tyrosine kinase inhibitors (TKIs) over the past two decades has shown that, despite the apparent therapeutic benefit, nearly 30% of patients with chronic myelogenous leukemia (CML) display primary resistance or intolerance to TKIs, and approximately 25% of those treated are forced to switch TKIs at least once during therapy due to acquired resistance. Safe and effective treatment modalities targeting leukemic clones that escape TKI therapy could hence be game changers in the professional management of these patients. Here, we aimed to investigate the efficacy of a novel therapeutic oligonucleotide of unconventional design, called ASP210, to reduce BCR-ABL1 mRNA levels in TKI-resistant CML cells, with the assumption of inducing their apoptosis. Imatinib- and dasatinib-resistant sublines of BCR-ABL1 positive MOLM-7 and CML-T1 cells were established and exposed to 0.25 and 2.5 µM ASP210 for 10 days. RT-qPCR showed a remarkable reduction of the target mRNA level by >99% after a single application. Cell viability was monitored daily by trypan blue staining. In response to the lack of driver oncoprotein BCR-ABL1, TKI-resistant CML cells underwent apoptosis regardless of the presence of the clinically relevant T315I mutation by day 5 after re-dosing with ASP210. The effect was selective for cancer cells, indicating a favorable safety profile for this therapeutic modality. Furthermore, the spontaneous uptake and high intracellular concentrations of ASP210 suggest its potential to be effective at relatively low doses. The present findings suggest that ASP210 is a promising therapeutic avenue for CML patients who fail to respond to TKI therapy.

2.
Int J Nanomedicine ; 19: 4103-4120, 2024.
Article in English | MEDLINE | ID: mdl-38736658

ABSTRACT

Introduction: Gold nanoparticles are promising candidates as vehicles for drug delivery systems and could be developed into effective anticancer treatments. However, concerns about their safety need to be identified, addressed, and satisfactorily answered. Although gold nanoparticles are considered biocompatible and nontoxic, most of the toxicology evidence originates from in vitro studies, which may not reflect the responses in complex living organisms. Methods: We used an animal model to study the long-term effects of 20 nm spherical AuNPs coated with bovine serum albumin. Mice received a 1 mg/kg single intravenous dose of nanoparticles, and the biodistribution and accumulation, as well as the organ changes caused by the nanoparticles, were characterized in the liver, spleen, and kidneys during 120 days. Results: The amount of nanoparticles in the organs remained high at 120 days compared with day 1, showing a 39% reduction in the liver, a 53% increase in the spleen, and a 150% increase in the kidneys. The biological effects of chronic nanoparticle exposure were associated with early inflammatory and fibrotic responses in the organs and were more pronounced in the kidneys, despite a negligible amount of nanoparticles found in renal tissues. Conclusion: Our data suggest, that although AuNPs belong to the safest nanomaterial platforms nowadays, due to their slow tissue elimination leading to long-term accumulation in the biological systems, they may induce toxic responses in the vital organs, and so understanding of their long-term biological impact is important to consider their potential therapeutic applications.


Subject(s)
Gold , Kidney , Liver , Metal Nanoparticles , Serum Albumin, Bovine , Spleen , Animals , Gold/chemistry , Gold/pharmacokinetics , Gold/toxicity , Gold/administration & dosage , Metal Nanoparticles/chemistry , Metal Nanoparticles/toxicity , Metal Nanoparticles/administration & dosage , Spleen/drug effects , Serum Albumin, Bovine/chemistry , Serum Albumin, Bovine/pharmacokinetics , Kidney/drug effects , Kidney/metabolism , Tissue Distribution , Liver/drug effects , Liver/metabolism , Mice , Male , Particle Size
3.
Heliyon ; 8(11): e11595, 2022 Nov.
Article in English | MEDLINE | ID: mdl-36419669

ABSTRACT

Fundamental studies investigating the biological effects induced by nanoparticles (NPs) explicitly require the correct assessment of their intracellular concentration. Ultrasensitive atomic absorption spectroscopy (AAS) is perceived as one of the gold standard methods for quantifying internalized NPs. Besides its limitation to metal-based NPs though, AAS also requires specific infrastructure and tedious sample preparation and handling, making it time-consuming and cost-intensive. Herein we report on a reliable, rapid, and affordable alternative to AAS - plate reader spectroscopy (PRS), which offers an accessible option for everyday laboratory use without sophisticated instrumentation. Our results demonstrate, that following a proper methodological approach, data on intracellular concentration of NPs obtained by PRS are fully comparable to AAS results. Specifically, the intracellular concentration of magnetite NPs coated with sodium oleate and bovine serum albumin in human alveolar A549 cells was assessed by PRS and AAS in parallel, with a remarkable correlation coefficient of R = 0.9914.

4.
Viruses ; 14(4)2022 03 25.
Article in English | MEDLINE | ID: mdl-35458415

ABSTRACT

In only two years, the coronavirus disease 2019 (COVID-19) pandemic has had a devastating effect on public health all over the world and caused irreparable economic damage across all countries. Due to the limited therapeutic management of COVID-19 and the lack of tailor-made antiviral agents, finding new methods to combat this viral illness is now a priority. Herein, we report on a specific oligonucleotide-based RNA inhibitor targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It displayed remarkable spontaneous cellular uptake, >94% efficiency in reducing RNA-dependent RNA polymerase (RdRp) RNA levels in transfected lung cell lines, and >98% efficiency in reducing SARS-CoV-2 RNA levels in samples from patients hospitalized with COVID-19 following a single application.


Subject(s)
COVID-19 Drug Treatment , Oligonucleotides , SARS-CoV-2 , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , Humans , Oligonucleotides/pharmacology , Oligonucleotides/therapeutic use , RNA, Viral/genetics , RNA-Dependent RNA Polymerase/genetics , RNA-Dependent RNA Polymerase/metabolism , SARS-CoV-2/genetics
5.
Beilstein J Nanotechnol ; 12: 270-281, 2021.
Article in English | MEDLINE | ID: mdl-33842184

ABSTRACT

The efficient entry of nanotechnology-based pharmaceuticals into target cells is highly desired to reach high therapeutic efficiency while minimizing the side effects. Despite intensive research, the impact of the surface coating on the mechanism of nanoparticle uptake is not sufficiently understood yet. Herein, we present a mechanistic study of cellular internalization pathways of two magnetic iron oxide nanoparticles (MNPs) differing in surface chemistry into A549 cells. The MNP uptake was investigated in the presence of different inhibitors of endocytosis and monitored by spectroscopic and imaging techniques. The results revealed that the route of MNP entry into cells strongly depends on the surface chemistry of the MNPs. While serum bovine albumin-coated MNPs entered the cells via clathrin-mediated endocytosis (CME), caveolin-mediated endocytosis (CavME) or lipid rafts were preferentially involved in the internalization of polyethylene glycol-coated MNPs. Our data indicate that surface engineering can contribute to an enhanced delivery efficiency of nanoparticles.

6.
RSC Adv ; 10(40): 23916-23929, 2020 Jun 19.
Article in English | MEDLINE | ID: mdl-35517346

ABSTRACT

Drug-induced nephrotoxicity is a frequent adverse event and a dose-limiting factor in patient treatment and is a leading cause of prospective drug attrition during pharmaceutical development. Despite the obvious benefits of nanotherapeutics in healthcare strategies, the clearance of imaging agents and nanocarriers from the body following their therapeutic or diagnostic application generates concerns about their safety for human health. Considering the potency of nanoparticles and their massive utilization in biomedicine the impact of magnetic nanoparticles (MNPs) on cells forming the filtration apparatus of the kidney was studied. Using primary mouse renal glomerular podocytes and mesangial cells, we investigated their response to exposure to magnetic nanoparticles coated with polyethylene glycol and bovine serum albumin. Cultured podocytes were more sensitive to MNPs than mesangial cells displaying signs of cell damage and stronger inflammatory response. Both types of MNPs induced the remodeling of actin fibers, affected the cell shape and triggered expression of inflammatory cytokines TNFα and IL-6 in podocytes. On the other hand, iNOS was induced in both renal cell types but only by MNPs with a polyethylene glycol coating. Our results have revealed that the type of cell and the type of nanoparticle coating might be the strongest determinants of cellular response toward nanoparticle exposure. Differences in susceptibility of cells to MNPs might be evident also between neighboring renal cell subpopulations integrally forming functional sub-units of this organ.

7.
Article in English | MEDLINE | ID: mdl-31561890

ABSTRACT

Progressive expansion of nanomaterials in our everyday life raises concerns about their safety for human health. Although kidneys are the primary organs of xenobiotic elimination, little attention has been paid to the kidneys in terms of nanotoxicological studies up to now. Here we investigate the cytotoxic and genotoxic potential of four solid-core uncoated inorganic nanoparticles (TiO2NPs, SiO2NPs, Fe3O4NPs and AuNPs) using the human renal proximal tubule epithelial TH1 cells. To mimic the in vivo conditions more realistic, TH1 cells were exposed in vitro to inorganic NPs under static as well as dynamic conditions for 3 h and 24 h. The medium throughput alkaline comet assay (12 minigels per slide) was employed to evaluate the impact of these NPs on genome integrity and their capacity to produce oxidative lesions to DNA. The accumulation and localization of studied inorganic NPs inside the cells was monitored by transmission electron microscopy (TEM) and the efficacy of internalization of particular NPs was determined by atomic absorption spectroscopy (AAS) and inductively coupled plasma mass spectrometry (ICP-MS). From all the tested NPs, only Fe3O4NPs induced a slight cytotoxicity in TH1 cells exposed to high concentrations (>700 µg/ml) for 24 h. On the other hand, the inorganic NPs did not increase significantly the level of DNA strand breaks or oxidative DNA damage regardless of the treatment mode (static vs. dynamic conditions). Interestingly, substantial differences were observed in the internalized amount of inorganic NPs in TH1 cells exposed to equivalent (2.2 µg/ml) concentration. Fe3O4NPs were most efficiently taken up while the lowest quantity of particles was determined in TiO2NPs-treated cells. As the particle size and shape of individual inorganic NPs in culture medium was nearly identical, it is reasonable to suppose that the chemical composition may contribute to the differences in the efficacy of NPs uptake.


Subject(s)
Epithelial Cells/drug effects , Kidney Tubules, Proximal/drug effects , Metal Nanoparticles/toxicity , Th1 Cells/drug effects , Comet Assay , DNA Breaks , DNA Damage , Dynamic Light Scattering , Gold/toxicity , Humans , Kidney Tubules, Proximal/cytology , Magnetite Nanoparticles/toxicity , Oxidative Stress , Phagocytosis , Rheology , Silicon Dioxide/toxicity , Single-Cell Analysis , Time Factors , Titanium/toxicity
8.
Cancer Med ; 7(7): 3406-3410, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29905026

ABSTRACT

Chronic myelogenous leukemia (CML) is commonly treated with tyrosine kinase inhibitors (TKIs) that inhibit the pro-leukemic activity of the BCR-ABL1 oncoprotein. Despite the therapeutic progress mediated by TKI use, off-target effects, treatment-induced drug resistance, and the limited effect of these drugs on CML stem cells (SCs) are major drawbacks frequently resulting in insufficient or unsustainable treatment. Therefore, intense research efforts have focused on development of improved TKIs and alternative treatment strategies to eradicate CML SCs. Alongside efforts to design superior protein inhibitors, the need to overcome the poor therapeutic effect of TKIs on CML SCs has led to a renaissance of antisense strategies, as they are reported as effective in more primitive cell types. Despite the greater drug design flexibility offered by antisense sequence variability and remarkable chemical improvements, antisense drugs exhibit unacceptable levels of off-target effects, precluding them from large-scale clinical testing. Recent advances in antisense drug design have led to a pioneering mRNA recognition concept that may offer a helping hand in eliminating off-target effects, and has potential to bridge the gap between research and clinical practice.

9.
Carbohydr Polym ; 192: 104-110, 2018 Jul 15.
Article in English | MEDLINE | ID: mdl-29691001

ABSTRACT

Ionically crosslinked chitosan/tripolyphosphate (Chit/TPP) particles have been widely tested in biomedical applications, particularly as potential carriers for controlled drug delivery. Since Chit/TPP particles are typically prepared under acidic conditions, their application in physiological environment and correct evaluation of biological data ultimately require knowledge on their physico-chemical properties and overall behaviour at physiological pH, as they may differ substantially from those exhibited after preparation. In this study, Chit/TPP complexes prepared at pH 4.43 were exposed to a physiological and slightly alkaline pH of 7.42 and 8.90, respectively, and analysed by inductively coupled plasma mass spectrometry and Fourier transform infrared spectroscopy with attenuated total reflectance for TPP content. In parallel, osmolarity measurements as well as theoretical calculations were used to interpret the composition and behaviour of Chit/TPP complexes upon pH elevation. Exposure of Chit/TPP complexes to a pH in the physiological range resulted in their practically complete dissociation into free chitosan chains. This leads to a significant consequence that Chit/TPP particles prepared at acidic pH do not exist under physiological conditions.

10.
Sci Rep ; 8(1): 1637, 2018 01 26.
Article in English | MEDLINE | ID: mdl-29374272

ABSTRACT

A next-generation cure for type 1 diabetes relies on immunoprotection of insulin-producing cells, which can be achieved by their encapsulation in microspheres made of non-covalently crosslinked hydrogels. Treatment success is directly related to the microsphere structure that is characterized by the localization of the polymers constituting the hydrogel material. However, due to the lack of a suitable analytical method, it is presently unknown how the microsphere structure changes in vivo, which complicates evaluation of different encapsulation approaches. Here, confocal Raman microscopy (CRM) imaging was tailored to serve as a powerful new tool for tracking structural changes in two major encapsulation designs, alginate-based microbeads and multi-component microcapsules. CRM analyses before implantation and after explantation from a mouse model revealed complete loss of the original heterogeneous structure in the alginate microbeads, making the intentionally high initial heterogeneity a questionable design choice. On the other hand, the structural heterogeneity was conserved in the microcapsules, which indicates that this design will better retain its immunoprotective properties in vivo. In another application, CRM was used for quantitative mapping of the alginate concentration throughout the microbead volume. Such data provide invaluable information about the microenvironment cells would encounter upon their encapsulation in alginate microbeads.

11.
Trends Mol Med ; 23(8): 671-674, 2017 08.
Article in English | MEDLINE | ID: mdl-28732687

ABSTRACT

Despite the massive global spend on biology-driven drug discovery, tackling the issue of side effects and adverse events resulting from drug promiscuity represents a persistent challenge. Although delivering authentic medical innovations today is more complex than ever, minimization of off-target effects should be a priority.


Subject(s)
Drug Design , Animals , Humans
14.
Nanomedicine ; 13(1): 69-80, 2017 01.
Article in English | MEDLINE | ID: mdl-27593490

ABSTRACT

Iron oxide nanoparticles are one of the most promising types of nanoparticles for biomedical applications, primarily in the context of nanomedicine-based diagnostics and therapy; hence, great attention should be paid to their bio-safety. Here, we investigate the ability of surface-modified magnetite nanoparticles (MNPs) to produce chromosome damage in human alveolar A549 cells. Compared to control cells, all the applied MNPs increased the level of micronuclei moderately but did not cause structural chromosomal aberrations in exposed cells. A rise in endoreplication, polyploid and multinuclear cells along with disruption of tubulin filaments, downregulation of Aurora protein kinases and p53 protein activation indicated the capacity of these MNPs to impair the chromosomal passenger complex and/or centrosome maturation. We suppose that surface-modified MNPs may act as aneugen-like spindle poisons via interference with tubulin polymerization. Further studies on experimental animals revealing mechanisms of therapeutic-aimed MNPs are required to confirm their suitability as potential anti-cancer drugs.


Subject(s)
Aneugens/pharmacology , Antineoplastic Agents/pharmacology , Magnetite Nanoparticles/chemistry , Spindle Apparatus/drug effects , A549 Cells , DNA Damage , Humans , Micronuclei, Chromosome-Defective , Nanomedicine , Tubulin/drug effects
15.
Mater Sci Eng C Mater Biol Appl ; 70(Pt 1): 161-168, 2017 Jan 01.
Article in English | MEDLINE | ID: mdl-27770877

ABSTRACT

Comprehensive characterization of nanoparticles associated with investigation of their cellular uptake creates the basis on which fundamental in vitro and in vivo studies can be built. In this work, a complex analysis of various surface-modified magnetite nanoparticles in biologically relevant environment is reported and the promotion of incorrect characterization into the results obtained from model biological experiments leading to false conclusions is demonstrated. Via a bottom-up approach from particle characterization by DLS towards interpretation of biological data based on cellular uptake, this work draws attention to the systematic propagation of errors stemming from inaccurate determination of input parameters for DLS, improper selection of particle size distribution, inadequate sampling, unknown colloidal behavior and the omission of fraction of particles complying with the internalization threshold. In addition, cellular uptake depending on the number of treated cells is shown. The definition of cellular uptake efficacy reflecting the size distribution of particles beside their absolute internalization is postulated.


Subject(s)
Chemical Phenomena , Intracellular Space/metabolism , Magnetite Nanoparticles/chemistry , A549 Cells , Colloids/chemistry , Dynamic Light Scattering , Endocytosis , Humans , Hydrodynamics , Magnetite Nanoparticles/ultrastructure , Particle Size , Solutions
16.
Carbohydr Polym ; 151: 488-499, 2016 Oct 20.
Article in English | MEDLINE | ID: mdl-27474593

ABSTRACT

The controlled preparation of chitosan particles is far from being trivial due to a considerable number of experimental parameters. For chitosan-tripolyphosphate (TPP) particles we evaluate the impact of chemical (type of chitosan, concentration, chitosan to TPP ratio, pH, ionic strength) and process factors (dialysis, stirring rate, rate of TPP addition, temperature, needle diameter) on the size and colloidal stability. The particles were prepared at pH=6.0 at which chitosan adopts the coiled conformation that is discussed as the dominant factor in controlling the stoichiometry of crosslinking reaction shifted towards TPP. These conditions result in identical particle size around 400nm and zeta potential around 22mV. The colloidal stability evaluated 24 hours after preparation depends on the amount of TPP during crosslinking. Under the same conditions, the colloidal stability up to 1 month is demonstrated. Several recommendations are provided to increase the control over formation of chitosan-TPP particles.

17.
Oncotarget ; 7(22): 33016-24, 2016 May 31.
Article in English | MEDLINE | ID: mdl-27145281

ABSTRACT

Little is known about the function and phenotype of leukemic stem cells (LSCs) in chronic myeloid leukemia (CML) or about specific markers that discriminate LSCs from normal hematopoietic stem cells (HSCs). CD26 has recently been described as a specific marker of CML LSCs. In the current study, we investigated this marker in a cohort of 31 unselected CML patients. BCR/ABL1 positivity was analyzed in highly enriched stem cell fractions using fluorescence in situ hybridization (FISH) and reverse transcription PCR (RT-PCR). The proportion of CD26+ LSCs and CD26- HSCs varied considerably among the patients analyzed, and the percentage of CD26+ cells correlated with leukocyte count. The CD26 expression robustly discriminated LSCs from HSCs. This required a strict gating of the stem cell compartment. Thus, in patients with very low LSC or HSC numbers, only the highly sensitive RT-PCR method discriminated between clonal and non-clonal cells, while a robust FISH analysis required larger numbers of cells in both compartments. Finally, our data show that the numbers of CD26+ CML LSCs correlate with responses to treatment with BCR-ABL1 inhibitors.


Subject(s)
Dipeptidyl Peptidase 4/biosynthesis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Neoplastic Stem Cells/immunology , Dipeptidyl Peptidase 4/immunology , Humans , Immunophenotyping , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology , Neoplastic Stem Cells/pathology , Prognosis
19.
Toxicol Lett ; 226(3): 303-13, 2014 May 02.
Article in English | MEDLINE | ID: mdl-24614527

ABSTRACT

The generation of reactive oxygen species (ROS) has been proposed as the underlying mechanism involved in the genotoxicity of iron oxide nanoparticles. The data published to date are, however, inconsistent, and the mechanism underlying ROS formation has not been completely elucidated. Here, we investigated the capacity of several surface-modified magnetite nanoparticles (MNPs) to generate ROS in A549 human lung adenocarcinoma epithelial cells and HEL 12469 human embryonic lung fibroblasts. All MNPs, regardless of the coating, induced significant levels of DNA breakage in A549 cells but not in HEL 12469 cells. Under the same treatment conditions, variable low levels of intracellular ROS were detected in both A549 and HEL 12469 cells, but compared with control treatment, none of the coated MNPs produced any significant increase in oxidative damage to DNA in either of these cell lines. Indeed, no significant changes in the total antioxidant capacity and intracellular glutathione levels were observed in MNPs-treated human lung cell lines regardless of surface coating. In line with these results, none of the surface-modified MNPs increased significantly the GPx activity in A549 cells and the SOD activity in HEL 12469 cells. The GPx activity was significantly increased only in SO-Fe3O4-treated HEL 12469 cells. The SOD activity was significantly increased in SO-PEG-PLGA-Fe3O4-treated A549 cells but significantly decreased in SO-Fe3O4-treated A549 cells. Our data indicate that oxidative stress plays, at most, only a marginal role in the genotoxicity of surface-modified MNPs considered in this study in human lung cells.


Subject(s)
DNA Damage , Lung/drug effects , Magnetite Nanoparticles/toxicity , Reactive Oxygen Species/metabolism , Apoptosis , Cells, Cultured , Glutathione/analysis , Glutathione Peroxidase/metabolism , Humans , Lung/metabolism , Superoxide Dismutase/metabolism
20.
Hematol Oncol ; 32(2): 87-93, 2014 Jun.
Article in English | MEDLINE | ID: mdl-23963760

ABSTRACT

This multicentre study focused on monitoring imatinib mesylate (IMA) trough plasma (Ctrough ) and intracellular (IMA Cintrac ) concentrations in 228 chronic myelogenous leukaemia patients. The median of measured IMA Ctrough in our patient group was 905.8 ng ml (range: 27.7-4628.1 ng/ml). We found a correlation between IMA Ctrough and alpha 1-acid glycoprotein plasma concentrations (rS = 0.42; p < 0.001). All other analysed parameters revealed only weak (gender, dose of IMA per kg) or not significant (age, albumin, creatinine plasma concentration or body mass index) impact on measured IMA Ctrough. The IMA Ctrough decreased during the first 6 months and significantly increased later during treatment. The IMA Ctrough at the first month of therapy did not differ between patients with and without an optimal response at the 12th (p = 0.724) and 18th month (p = 0.135) of therapy. There were no significant differences in medians of IMA Ctrough between both groups measured during the first year of treatment. The IMA Cintrac during the first month were not different between patients with and without an optimal response at the 6th (p = 0.273) and the 12th month (p = 0.193) of therapy. Our data obtained from real life clinical practice did not find a benefit of routine and regular IMA Ctrough nor IMA Cintrac therapeutic drug monitoring in chronic myelogenous leukaemia patients or for subsequent adjustments of the IMA dose based on these results. Moreover, actual alpha 1-acid glycoprotein plasma concentration should be used for proper interpretation of IMA Ctrough results.


Subject(s)
Antineoplastic Agents/blood , Antineoplastic Agents/therapeutic use , Benzamides/blood , Benzamides/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Piperazines/blood , Piperazines/therapeutic use , Pyrimidines/blood , Pyrimidines/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/pharmacokinetics , Benzamides/pharmacokinetics , Female , Humans , Imatinib Mesylate , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism , Male , Middle Aged , Piperazines/pharmacokinetics , Pyrimidines/pharmacokinetics , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...